key: cord-0898999-bsobuwl2
authors: Ghaebi, Mahnaz; Osali, Abdolreza; Valizadeh, Hamed; Roshangar, Leila; Ahmadi, Majid
title: Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances
date: 2020-06-18
journal: J Cell Physiol
DOI: 10.1002/jcp.29771
sha: a4c9ee331f28f675204b5c51c4677bf46e59db07
doc_id: 898999
cord_uid: bsobuwl2

The ongoing outbreak of the recently emerged 2019 novel coronavirus (nCoV), which has seriously threatened global health security, is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with high morbidity and mortality. Despite the burden of the disease worldwide, still, no licensed vaccine or any specific drug against 2019‐nCoV is available. Data from several countries show that few repurposed drugs using existing antiviral drugs have not (so far) been satisfactory and more recently were proven to be even highly toxic. These findings underline an urgent need for preventative and therapeutic interventions designed to target specific aspects of 2019‐nCoV. Again the major factor in this urgency is that the process of data acquisition by physical experiment is time‐consuming and expensive to obtain. Scientific simulations and more in‐depth data analysis permit to validate or refute drug repurposing opportunities predicted via target similarity profiling to speed up the development of a new more effective anti‐2019‐nCoV therapy especially where in vitro and/or in vivo data are not yet available. In addition, several research programs are being developed, aiming at the exploration of vaccines to prevent and treat the 2019‐nCoV. Computational‐based technology has given us the tools to explore and identify potentially effective drug and/or vaccine candidates which can effectively shorten the time and reduce the operating cost. The aim of the present review is to address the available information on molecular determinants in disease pathobiology modules and define the computational approaches employed in systematic drug repositioning and vaccine development settings for SARS‐CoV‐2.

severe respiratory and enteric diseases in humans and animals (Fehr & Perlman, 2015) . The seventh human coronavirus also known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identified to be a novel deadly and highly contagious virus that quickly spread to over 150 countries. On March 11, the WHO declared the outbreak of a pandemic (Djalante, Shaw, & DeWit, 2020) . It is well recognized that the virus has an unusually high speed of transmission and can survive in the environment, on different surfaces for long hours, which poses a serious risk (Negahdaripour, 2020) . Moreover, the illness causes flu-like symptoms, and the reports show that one person infected can easily infect others (J. .

Even though coronavirus infection of humans was identified for the first time in 1960; however, scientific research in this area grew only following the outbreak of SARS coronavirus in the year 2003 (Drosten et al., 2003; Ksiazek et al., 2003) . In spite of the reaction from the scientific community that was instantaneous and nearly uniform, at the current state of our knowledge, vaccines for COVID-19 seem months or even years away (Nabel, 2013) . While there is still much to be understood about the SARS-CoV-2, considerable research efforts have been made to yield answers to the basic questions of the SARS-CoV-2 behavior. There is currently off-label use of antiviral drugs for the treatment of this novel virus of coronaviruses that are not totally effective but only partially satisfactory treatment available. There is an urgent need for effective and specific interventions to help tackle the growing global health burden of SARS-CoV-2. To develop an effective care plan for SARS-CoV-2 outbreak, it is vital to find new targets for novel therapeutic anti-SARS-CoV-2 approach. In de novo drug discovery, it is fundamental to understand the molecular entities and specific pathways driving the virus replication during infection. In this paper, we review the available information on molecular determinants in disease pathobiology modules. In addition, the computational approaches employed in systematic drug repositioning and vaccine development settings for SARS-CoV-2 are described. In this procedure, for example, instead of traditional epitope identification upon experimental techniques, being costly and time-consuming (Sanchez-Trincado, Gomez-Perosanz, & Reche, 2017) , predictive computational methods can be the key way for screening the large-scale peptide candidates. It is hoped that the proposed methodology will open up new avenues for the rapid identification of candidate drugs for the potential prevention and treatment of SARS-CoV-2.

Coronaviruses are enveloped single-stranded RNA viruses with one of the largest viral genomes found in the RNA viruses that the majority are disease-causing agents (Pyrc, Berkhout, & Van Der Hoek, 2007) . Several phylogenetic studies subdivided the coronaviruses into four genera known as alpha-CoVs, beta-CoVs, gamma-CoVs, and delta-CoVs, of which alpha-and beta-CoVs are pathogenic viruses for mammals and gamma-and delta-CoVs are known to infect mainly birds (Paules, Marston, & Fauci, 2020) . Most coronaviruses are addressed as common cold viruses in humans that are of zoonotic origin and cause a more serious disease in animals (Lake, 2020) . In general, the gene pools of Groups 1 and 2 coronaviruses are thought to have originated in bats which are the reservoir of diverse CoVs and further spread to humans through an intermediate host or sometimes directly (Cui, Li, & Shi, 2019) . Human coronaviruses are typically associated with respiratory tract diseases such as those observed in the common cold including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 and sometimes enteric illnesses. However, the emergence of highly pathogenic human coronavirus infections in the last two decades has greatly illuminated their potential to cause high morbidity and mortality in humans (Cockrell, Leist, Douglas, & Baric, 2018) . The recent coronaviruses SARS-CoV and MERS-CoV that are two representative members of the genus Betacoronavirus emerged into the human population as zoonotic infections and were the most serious endemic illnesses associated with high mortality in the years 2003 and 2012, respectively (Peck, Burch, Heise, & Baric, 2015) . While no case of SARS-CoV infection has been around since 2004, multiple sporadic cases of MERS-CoV have been reported in different countries. Despite the low interhuman transmissibility, MERS-CoV has been identified as an infectious disease associated with high mortality rates which is about 35% and much higher than that of SARS (~10%; Donnelly, Malik, Elkholy, Cauchemez, & Van Kerkhove, 2019; Fong, 2017) . It is likely that discrepancy in the outcome of MERS-CoV-and SARS-CoV-infections be explained by differential virus pathogenicity and virulence. The recently identified SARS-CoV-2 also belongs to the same Betacoronavirus genus.

The International Committee on Taxonomy of Viruses has named the novel strain coronavirus SARS-CoV-2, as it is very similar to the known SARS-CoV in terms of the whole genome sequence (R. Lu et al., 2020) . SARS-CoV-2 has a genomic size of~30 kilobases encoding several structural and nonstructural proteins. The major structural proteins, which form the viral particle, include spike (S), envelope (E), membrane (M), and the nucleocapsid (N) protein. Preliminary studies show that the SARS-CoV-2 full-length genome is quite similar to SARS-CoV (P. Zhou et al., 2020) . However, as more data become available, the SARS-CoV-2 is undoubtedly distinct from SARS-CoV and from other bat origin coronaviruses and thus it is imperative to understand the novel coronavirus demanding immediate treatment to develop effective interventions targeting SARS-CoV-2. In the next phase, researchers and vaccine companies will further develop new vaccines for controlling and preventing this highly pathogenic virus.

3 | THERAPEUTIC OPTIONS FOR 2019-nCoV 3.1 | Perspectives on targeting "structural" proteins of There is currently no approved treatment for COVID-19 in humans, and up to now, a number of antiviral treatments such as ribavirin, primarily have been used based on the experiences from SARS and MERS medication (Singhal, 2020) . In addition, using chloroquine 2 | phosphate, an old antimalarial drug, is found with limited success in patients with COVID-19 (Gao, Tian, & Yang, 2020) . 2019-nCoV is genetically closely related to SARS coronavirus (about 79% identity) and MERS-CoV (about 50%) but more similar (with 88%) to two batderived SARS-like coronaviruses (R. Lu et al., 2020) . This virus is found to be a bat CoVs of the genus Betacoronavirus, however, has displayed large genetic distances to its close relatives to be considered a new human coronavirus. However, the modeling study did indicate a similar structure in receptor-binding domain (RBD) of 2019-nCoV to that of SARS-CoV with variations at some key amino acid residues. Emerging evidence suggest that 2019-nCoV might be bound to the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2) as a functional cell receptor in human (R. Lu et al., 2020) .

Clinical features of 2019-nCoV-infected patients indicate multiple organ failure in addition to pneumonia. ACE2 acting in a first key step of 2019-nCoV infection may help explain the clinical features of other systems observed in these patients. ACE2 is expressed extensively in the endothelium of the heart, liver, kidney, testis, and intestine (M. Yang, Zhao, & Zhang, 2020) and 2019-nCoV may probably infect any tissues where ACE2 is available. The ongoing works dissecting genetic molecular interactions highlight that SARS-CoV-2 differ in several critical residues at RBD (particularly Gln493) from other SARS strains leading to high-affinity interactions with ACE2 receptors, being significantly more contagious than those other viruses as a result (Wan, Shang, Graham, Baric, & Li, 2020) . One suggest that SARS-CoV-specific human monoclonal antibody, CR3022, but not the other SARS-CoV antibodies (e.g., m396, CR3014), may be effective in neutralizing 2019-nCoV and blocking its cell infection . At present, numerous attempts are being made to develop monoclonal antibodies that are specific and effective against 2019-nCoV. There may be more similarities in the mechanisms of cell entry for 2019-nCoV and SARS-CoV which employ ACE2 as entry receptor and the cellular serine protease called transmembrane protease, serine 2 for activating S-protein for host cell entry (Hoffmann et al., 2020) which might hopefully work as candidate therapeutic target for anti-2019-nCoV intervention (Hoffmann et al., 2020) . Thus, in this context, serine protease inhibitor camostat mesylate that is approved for human use in a different indication may provide an effective therapeutic option for the treatment of 2019-nCoV-infected patients (Kawase, Shirato, van der Hoek, Taguchi, & Matsuyama, 2012; Y. Zhou et al., 2015) . In another effort to limit 2019-nCoV infection, furin inhibitors have been reported to develop as a specific antiviral treatment (Coutard et al., 2020) . As the priming of viral envelope glycoproteins (such spike [S] protein) by the proteases of the target cells is essential for cell tropism and pathogenicity of virus, the efficacy and extent of this cleavage event may have implication in the development of antiviral agents. Human furin is a protease highly expressed in lungs, which cleaves the 2019-nCoV S-protein at a specific conserved site absent in SARS-CoV sequences (Bassi, Zhang, Renner, & Klein-Szanto, 2017) and thereby generates mature infectious virus particles. Overall, because of the fact that S-protein relates to degrees of pathogenicity, transmissibility, and pandemic potential, S-protein-based antiviral therapies offer an attractive and seemingly efficient modality into the area of anti-nCoV treatment (Jiang, He, & Liu, 2005; X. Li, Geng, Peng, Meng, & Lu, 2020) . Treatment regimens based on the use of S-protein-based therapeutics include antagonists of RBD-ACE2 interaction, inhibitors of S-protein cleavage proteases, neutralizing antibodies, S-protein inhibitors, and small interfering RNAs (Malik et al., 2020) . Nevertheless, a potential concern for the treatment of COVID-19 infection is the emergence of drug resistance by the rapid genomic evolution of virus during therapy. The higher risk of drug resistance has most often been noted to occur when targeting single virus proteins (Zumla, Chan, Azhar, Hui, & Yuen, 2016) . Even though these therapeutic strategies have demonstrated in vitro efficacy, they have not undergone animal or clinical testing so far and may, therefore, be of limited use in our present COVID-19 problem.

It is indicated that the key to the development of new drugs able to control the cause of the recent outbreak of the deadly viral pneumonia in China requires the identification of a conserved target region within the whole Coronavirus genus (H. Yang et al., 2005) . Despite all structural proteins including S, E, M, and N proteins, nonstructural proteins (NSPs) withstand considerable sequence variation among different CoVs (Woo et al., 2005) . NSPs responsible for viral replication and transcription may be adopted to target CoV. The SARS-CoV encodes 16 NSPs as potential virulence factors. Among these NSPs, an RNA-dependent RNA polymerase (RdRp), the NSP12, which is the central subunit of the CoV replicative machinery and its essential cofactors NSP7 and NSP8 play a crucial role in the replication of the SARS-CoV genome (Kirchdoerfer & Ward, 2019; Subissi et al., 2014) .

Accordingly, there should be possibly interference with the binding of NSP7 or NSP8 to NSP12 to inhibit the RdRp activity of NSP12 for the development of novel antiviral agents. As the comparative analyses of their amino acid sequences show high similarity with NSP7 (98.8%) and NSP8 (97.5%) of SARS-CoV (Ruan et al., 2020) , screening for compounds disrupting NSP12-NSP7-NSP8 complex may evolve as novel therapies of SARS-CoV-2. Based on virtual screening and docking methods, seven compounds (Saquinavir, Tipranavir, Lonafarnib, Tegobuvir, Olysio, Filibuvir, and Cepharanthine) have been GHAEBI ET AL.

| 3 suggested to have potential as efficacious new inhibitors of virus replication process (Ruan et al., 2020) offering more opportunities for clinical assessment of anti-SARS-CoV-2 drugs.

Usually, beta-coronaviruses produce a~800 kDa polypeptide that is posttranscriptionally cleaved at certain processing sites into separate subunits. The papain-like protease and 3-chymotrypsin-like protease (3CL pro ) are main proteases usually responsible for this proteolytic processing to generate various NSPs and are thus important for viral replication (Anand, Ziebuhr, Wadhwani, Mesters, & Hilgenfeld, 2003) . Recent studies revealed that 3CL pro is conserved in SARS-CoV-2 having 12-point mutations identified in the receptorbinding site that affects its binding ability to some medicinal plant compounds already used to treat viral diseases like inhibitor of SARS-CoV 3CL pro named ML188. Therefore, further optimization and drug development efforts were made to develop new compounds to inhibit SARS-CoV-2 3CL pro and the results identified nine novel natural compounds predicted to bind with the receptor-binding site of SARS-CoV-2 3CL pro which possess therapeutic activities (ul Qamar, Alqahtani, Alamri, & Chen, 2020). These investigations lack experimental validation, and to further address this anti-COVID-19 drug discovery with putative clinical application, more in vitro and in vivo studies are required. The enzyme Nsp13 helicase another potential target in the viral replication apparatus has been investigated in SARS-CoV-2 and could be structurally characterized by computational methods. Its nucleotide sequence predicted a protein of 596 amino acids. Similar to previous reports, molecular dynamics simulations together with virtual screening efforts were applied to identify the interaction profile of important binding site residues of SARS-CoV-2 Nsp13 helicase and potential therapeutic small molecules to find potent and selective inhibitors against SARS-CoV-2 (Mirza & Froeyen, 2020) . In silico predictions were used for determining ADME parameters of the identified potential hits against SARS-CoV-2 Nsp13 target, such as absorption, distribution, metabolism, elimination, toxicity (ADME-Tox) and resulting top hits were selected following removal of hits that exhibited poor ADMET-Tox found to contain highrisk chemical groups (Mirza & Froeyen, 2020) .

To improve control strategies, the research studies have attempted to develop effective treatments and prophylactic strategies including vaccination. Considering the cost per cured subject, vaccination appears more favorable. Alternatively, with rising morbidity and death rates, the benefit of the vaccine in reducing the disease burden will be higher. For this, the rest of the review will focus on what is known about the development of vaccine against COVID-19. Table 1 ) or plan to do so within a few months (Table 2) .

Although the virus's S-protein is considered a promising immunogen for inclusion in a nucleic acid COVID-19 vaccine, there continues to be debate over the best approach to ensure optimal immune response. For example, in the current debate, target antigen design in a full-length protein or the receptor-binding domain is challenging (Lurie et al., 2020) . However, several areas of consensus that are herein disclosed have emerged in this area. Beginning from the basics, it has been demonstrated that immune response to coronavirus infection or vaccination involves early neutralizing immunoglobulin G (IgG) antibody response against viral surface proteins (Zand & Wang, 2020) . There is also some evidence that coronaviruses make use of certain antibodies for entry to the cell as an alternative mechanism of target cell binding . It is also clinically demonstrated that sera from SARS patients apparently contain both neutralizing IgG antibodies and those that cause ADE . This is particularly important when modeling optimal vaccine strategy for reducing severe disease. Of note, within the different vaccine types (except for live-attenuated virus vaccines), the general goal is to induce adaptive immune response against S or N viral proteins and also the increase in highaffinity IgG production is of the utmost importance for planning vaccine actions. These data collectively suggest that one approach may be to manipulate and modify the protein sequences to disable the potential for ADE if possible (Zand & Wang, 2020) . In addition,

given that such an adverse effect may be associated with T helper type 2 (Th2) immune responses, extended human safety testing will be critical. To this point, using a suitable adjuvant with a capacity to trigger a type 1T helper (Th1) response and high neutralizing antibody titers, theoretically, is likely to be protective to avoid immunopathology (Lurie et al., 2020) . It worth noting that the use of an adjuvant in the vaccine is a reasonable approach in a pandemic that may substantially reduce the amount of vaccine material required for immunization. Owing to the limited worldwide production capacity for vaccine, this strategy will allow more vaccine doses to be produced for widespread vaccination of populations and therefore contributes to protection of more people .

The E protein has also been proposed as an attractive vaccine target for developing live-attenuated vaccines, which is based on prior studies of related coronaviruses that cause MERS and SARS-CoV (Almazán et al., 2013) . For both SARS and MERS-CoV, the construction of an attenuated virus deleted in E protein could result in a replication-competent but propagation-defective virus that supports the efficacy of the attenuated viruses as vaccine candidates (Almazán et al., 2013) . Deletion of E protein can be accomplished to 2019-nCoV and it is expected to lead to a similar breakthrough given approaches have been carried out to elucidate the genetic and antigenic properties of the virus to accelerate novel vaccine design.

Peptide-based vaccines have received more attention due to their ease of production by the chemical synthesis of dominant protective epitopes (Dudek, Perlmutter, Aguilar, Croft, & Purcell, 2010) . Just as neutralizing the free virus particles before cell entry is required to prevent cells from being infected by COVID-19, rational vaccine design strategies based on the characterization of epitopes on the most exposed protein of the virus that can be recognized by B cell antibodies and T lymphocytes may be able to overcome the ongoing outbreak. Using immunoinformatics approach to find protein epi- the antigenicity analysis pointed out that only 13 MHC-I epitopes and 3 MHC-II epitopes had the antigenic propensity (Bhattacharya et al., 2020) . Furthermore, of the S-protein oligopeptides, the most immunogenic and uniquely viral epitopes were identified through comparative Homo sapiens-coronavirus proteome analysis. Using the Peptide Match program, the 2109-nCoV and the human proteomes were compared and searched for viral peptides that are absent in the human proteome to increase antiviral specificity and minimizing the risk for cross-reactions (Lucchese, 2020) . A total of 66 non-self sequences in the virus genome were obtained as a result that represents the best targets for vaccine development due to their potential for immunogenicity (Richman, Vonderheide, & Rech, 2019) .

In addition, the identification of the potential T cell epitopes Li et al., 2008) . The authors claim that immune targeting of SARS-CoV-derived B cell and T cell epitopes that map identically to SARS-CoV-2 proteins may offer substantial protection against the new virus (Ahmed, Quadeer, & McKay, 2020) . What strengthens the idea is that the determined epitopes comprise no mutations in the available SARS-CoV-2 sequences (Ahmed et al., 2020) .

Since genomic variations of the pathogen have significant clinical consequences, the genetic diversity of SARS-CoV-2 and strategies to develop vaccine candidates are described in detail in the next section.

One hypothesis is that the rapid spread of SARS-CoV-2 may be due to its evolution driven by viral mutations. Understandably, the evolution of RNA viruses continues to occupy a great deal of attention (Dolan, Whitfield, & Andino, 2018) . The rapid evolution of RNA viruses that utilize a highly divergent RNA-dependent RNA polymerase is often more evident than those of DNA-based viruses.

In fact, enormous genetic diversity is a critical determinant of their adaptative capacity (Lauring, Frydman, & Andino, 2013) . Nucleotide substitution in DNA is often involved as one of the most important mechanisms provoking viral evolution in nature (Lauring & Andino, 2010) . In the last few months, genome-sequencing projects have been conducted by the worldwide scientific community to understand the evolutionary dynamics and characteristics of this results an ∼800 kDa polyprotein were described as the two most variable locations in the core genome (Ceraolo & Giorgi, 2020) .

Another important aspect of virus replication may be at the functional contact between virus and host. Several viruses, including coronaviruses, require host cellular factors to replicate (Zumla et al., 2016) . Furthermore, repeated observations in other families of RNA viruses indicate that many, if not most, mutations are surface-located and that the conserved residues are probably core residues of viral proteins (Cheng & Brooks III, 2013; Patel & Kukol, 2017; Warren, Wan, Conant, & Korkin, 2013) . (Deng, Hu, Wang, & Deng, 2012) . Subunit vaccines offer many advantages over live-attenuated or inactivated organisms.

Unlike inactivated or live-attenuated virus vaccines, subunit vaccines are known to provide better efficacy as they are unable to revert to the virulent form of the pathogen and eliminate the risk of incomplete inactivation, thus making them biologically safe; however, they typically require coadministration with adjuvants (Zhang et al., 2012) . Based on this information, the subunit candidates such as full-length S-protein and/or the RBD element of SARS-CoV-2 prove valuable for prevention against COVID-19 (Shang, Yang, Rao, & Rao, 2020) , though they are expensive to manufacture and need for repeated injections (Phillpotts, Venugopal, & Brooks, 1996) .

Moreover, subunit vaccines can be designed to contain well-characterized neutralizing epitopes defined as those epitopes which elicit a neutralizing antibody response but avoiding epitopes with pathological ADE effects to improve immunogenicity (Naz & Dabir, 2007) . Another scientific challenge for vaccine development may be dependent to the strategies of vaccine delivery. Evidence of respiratory tract infection and findings of SARS-2 in stool (Holshue et al., 2020; Q. Li et al., 2020) suggest that mucosal delivery routes by oral or aerosol administration of vaccine appear to be the possible modes of SARS-CoV-2 immunization.

Epidemiological studies have shown that the disease caused by SARS-CoV-2 is significantly associated with a higher age in which GHAEBI ET AL. | 9 individuals above 50 years of age often exhibit more severe pathology following SARS-CoV-2 infection and are more likely to die from infection. In many viral infections, the naive younger individuals experience milder manifestations of the disease. Because it affects the health of older people more strongly, vaccine as a public health measure, must protect this vulnerable population (Amanat & Krammer, 2020) . Unfortunately, it is precisely in this population that vaccines are the least efficacious because of immune senescence (Sambhara & McElhaney, 2009 ). As of current influenza vaccines, specific formulations including high-dose antigen or using an adjuvant may be particularly useful for this segment of the population (Amanat & Krammer, 2020; DiazGranados et al., 2013) . Interestingly, even if vaccination does not result in protection in all recipients, it is still able to stop the transmission of the virus and thereby benefits older individuals (Amanat & Krammer, 2020) .

Finally, once a successful SARS-2 vaccine is developed and available, the responsibility to let the global access to it should be a part of planning. Nonetheless, apart from the availability of the vaccine, still social, clinical, and economic hurdles face SARS-2 vaccine and vaccination programmes that include, for example, willingness of the public to get a new vaccination, the potential variation in efficiency for quite different populations, as well as severe adverse reactions arising from the new vaccine (Pang et al., 2020) .

Our review of the available relevant literature summarized the published information regarding COVID-19 vaccine research and development. In summary, extensive bioinformatics analysis, in the past few months, has helped provide a unique opportunity to a better understanding of determinants of immunogenicity, immunodominance, and structure-function relationships that can to a great extent reduce the experimental cost in epitope identification for vaccine design as well as limit the pool of peptides available for analysis. While research into such efforts is in its early stages, the prospect of a preventative or therapeutic vaccine seems realistic as a result of a more intense global cooperation and also by taking advantage of the gathered data on SARS and MERS. As data collection continues, we are getting closer to finding better ways to conquer this disease. First and foremost, accurate and up to date data on the status and timing of vaccine production and release must be accessible. Meanwhile, the collaboration of countries from all over the world is clearly needed in producing a preventive or therapeutically desired result.

The authors declare that there are no conflict of interests.

M. G. and M. A. were involved in drafting the manuscript. M. A. has critically reviewed the manuscript content.

Majid Ahmadi http://orcid.org/0000-0003-4787-5261

Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

Engineering a replicationcompetent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate

SARS-CoV-2 vaccines: Status report, immunity. Immunity

Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs

Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV

Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth

Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach

Genomic variance of the 2019-nCoV coronavirus

Can vaccine development be safely accelerated?

The SARS-CoV-2 vaccine pipeline: An overview

Viral capsid proteins are segregated in structural fold space

Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice

Vaccine designers take first shots at COVID-19

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Origin and evolution of pathogenic coronaviruses

Developments of subunit and VLP vaccines against influenza A virus

High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009-2010 season

Building resilience against biological hazards and pandemics: COVID-19 and its implications for the Sendai Framework

Mapping the evolutionary potential of RNA viruses

Worldwide reduction in MERS cases and deaths since

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Epitope discovery and their use in peptide based vaccines

Coronaviruses: An overview of their replication and pathogenesis

Emerging animal coronaviruses: First SARS and now MERS. Emerging Zoonoses. Emerging Infectious Diseases of the 21st Century

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Novel vaccine technologies essential components of an adequate response to emerging viral diseases

The pandemic pipeline

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

First case of 2019 novel coronavirus in the United States

Developing a low-cost and accessible COVID-19 vaccine for global health

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway

SARS vaccine development

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

A novel coronavirus associated with severe acute respiratory syndrome

What we know so far: COVID-19 current clinical knowledge and research

Quasispecies theory and the behavior of RNA viruses

The role of mutational robustness in RNA virus evolution

T cell responses to whole SARS coronavirus in humans

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Molecular immune pathogenesis and diagnosis of COVID-19

Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

EV71 vaccines: A milestone in the history of global vaccine development

Epitopes for a 2019-nCoV vaccine

Developing COVID-19 vaccines at pandemic speed

Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments

Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 RNA-dependent RNA polymerase and Nsp13 helicase

Designing tomorrow's vaccines

Peptide vaccines against cancer, infectious diseases, and conception

The battle against COVID-19: Where do we stand now?

Potential rapid diagnostics, vaccine and therapeutics for 2019 novel Coronavirus (2019-ncoV): A systematic review

Evolutionary conservation of influenza A PB2 sequences reveals potential target sites for small molecule inhibitors

Coronavirus infectionsmore than just the common cold

Coronavirus host range expansion and Middle East respiratory syndrome coronavirus emergence: Biochemical mechanisms and evolutionary perspectives

Genetic diversity and evolution of SARS-CoV-2. Infection

Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus

Identification of new human coronaviruses

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

2019-nCoV (Wuhan virus), a novel Coronavirus: Human-tohuman transmission, travel-related cases, and vaccine readiness

Insights into cross-species evolution of novel human coronavirus 2019-nCoV and defining immune determinants for vaccine development

Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade

Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12) of SARS-CoV-2. Preprints

Immunosenescence and influenza vaccine efficacy vaccines for pandemic influenza

Fundamentals and methods for T-and B-cell epitope prediction

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

A review of coronavirus disease-2019 (COVID-19)

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus

Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus

Molecular mechanism for antibody-dependent enhancement of coronavirus entry

Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates

Extreme evolutionary conservation of functionally important regions in H1N1 influenza proteome

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

EV71: An emerging infectious disease vaccine target in the Far East? Vaccine

Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Correction: Design of wide-spectrum inhibitors targeting coronavirus main proteases

More than pneumonia, the potential occurrence of multiple organ failure in 2019 novel coronavirus infection

Potential mechanisms of age related severity of COVID-19 Infection: Implications for vaccine development and convalescent serum therapy

LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Protease inhibitors targeting coronavirus and filovirus entry

Coronaviruses-drug discovery and therapeutic options

Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances